Multistep carcinogenesis of breast cancer and tumour heterogeneity

Journal of Molecular Medicine

Volumn 75, Issue 6, 1997, Pages 429-439

  Beckmann, Matthias W ^a   Niederacher, Dieter ^a   Schnüren, Hans Georg ^a   Gusterson, Barry A ^b   Bender, Hans Georg ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; Breast pathology; Carcinogenesis; Oncogenes; Tumour suppressor genes

Indexed keywords

ONCOPROTEIN;

BREAST CANCER; CARCINOGENESIS; CELL HETEROGENEITY; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME LOSS; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GERM LINE; MALIGNANT TRANSFORMATION; METASTASIS; MUTATION; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CARCINOGENS, ENVIRONMENTAL; FEMALE; HORMONES; HUMANS; RECEPTORS, CELL SURFACE; RECEPTORS, STEROID; RISK FACTORS; STEROIDS;

EID: 0030799482     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050128     Document Type: Review

References (150)

1. Garfinkel L, Boring CC, Heath Jr CW (1994) Changing trends: an overview of breast cancer incidence and mortality. Cancer 74:222-228
2. Anonymous (1995) Statistische Daten zur Krebsinzidenz. Robert Koch Institut, Berlin
3. Harris JR, Lippman ME, Veronesi U, Willett W (1992) Breast cancer. N Eng J Med 327:319-328
4. Henderson IC (1993) Risk factors for breast cancer. Cancer 71:2127-2140
5. Henson DE, Tarone RE (1994) Involution and the etiology of breast cancer. Cancer 74:424-429
6. Gusterson BA, Stratton M, Anbazhagan R (1996) The importance of human breast development in mammary carcinogenesis. In: Li JJ, Gustafasson JA, Nandi S, Sekely LI (eds) Hormonal carcinogenesis II. Springer, Berlin Heidelberg New York; pp 115-119
7. Busch H (1990) The final common pathway of cancer: presidential address. Cancer Res 50:4830-4838
8. Black DM (1994) The genetics of breast cancer. Eur J Cancer 30A: 1957-1961
9. El-Ashry D, Lippman ME (1994) Molecular biology of breast carcinoma. World J Surg 18: 12-20
10. Thompson WD (1994) Genetic epidemiology of breast cancer. Cancer 74:279-288
11. Virchow R (1855) Cellularpathologie. Arch Pathol Anat 8: 1-39
12. Rosen PP (1996) Invasive mammary carcinoma. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the breast. Lippincott-Raven, Philadelphia
13. Fearon ER, Vogelstein B (1990) A genetic model for coloreclal tumorigenesis. Cell 61:759-767
14. Cho KR, Vogelstein B (1992) Genetic alterations in the adenoma-carcinoma sequence. Cancer 70:1727-1731
15. Osborne MP (1996) Breast development and anatomy. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the breast. Lippincott-Raven, Philadelphia
16. World Health Organization (1981) Histological typing of breast tumors. In: Second international histological classification of tumours. World Health Organization, Geneva
17. Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146-150
18. Jensen RA, Page DL, Dupont WD (1989) Invasive breast cancer risk in women with sclerosing adenosis. Cancer 64: 1977-1981
19. Dupont WD, Page DL (1989) Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Hum Pathol 20:723-728
20. London SJ, Connolly JL, Schnitt SJ (1992) A prospective study of benign breast disease and the risk of breast cancer. JAMA 267:941-945
21. Dupont WD, Parl FF, Hartmann WH (1993) Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 71:1258-1262
22. Kessler LG, Feur EJ, Brown ML (1991) Projections of breast cancer burden to US women: 1990-2000. Prev Med 20: 170-1275
23. Holland R, Hendicks J (1994) Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation. Sem Diagn Pathol 11:181-189
24. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C (1996) Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 275:913-918
25. Faverly D, Holland R, Burgers L (1992) An original stereomicroscopic analysis of the mammary glandular tree. Virchows Archiv 115:421-426
26. Morrow M, Schnitt SJ, Harris JR (1996) Ductal carcinoma in situ. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the breast. Lippincott-Raven, Philadelphia
27. Page DL, Dupont WD, Rogers LW (1985) Atypical hyperplasic lesions of female breast: a long-term follow-up study. Cancer 55:2698-2672
28. Andersen JA (1977) Lobular carcinoma in situ of the breast: an approach to rational treatment. Cancer 39:2597-2580
29. Haagensen CD, Bodian C, Haagensen DE (1981) Lobular neoplasia (lobular carcinoma in situ) and breast carcinoma: risk and detection. Saunders, Philadelphia, pp 238-247
30. Key TJA, Pike MC (1988) The role of oestrogens and progestaszens in the epidemiology and prevention of breast cancer. Eur J Cancer 24:29-43
31. Russo J, Russo IH (1993) Developmental pattern of human breast and susceptibility to carcinogenesis. Eur J Cancer Prev 2 [Suppl 3]:85-100
32. Smith DF, Toft DO (1993) Steroid hormone receptors and their associated proteins. Mol Endocrinol 7:4-11
33. Lupulescu A (1993) Estrogen use and cancer risk: a review. Exp Clin Endocrinol 101:204-214
34. Pertschuk LP, Kim DS, Nayer K, Feldman JG, Eisenberg KB, Carter AC, Rong ZT, Thelmo WL, Fleisher J, Greene GL (1990) Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Cancer 66:1663-1670
35. Ozzello L, DeRosa C, Habif DV, Greene GL (1991) An immunohistochemical evaluation of progesterone receptor in frozen sections, paraffin sections, and cytologic imprints of breast carcinomas. Cancer 67:455-462
36. Mansour EG, Ravdin PM, Dressler L (1994) Prognostic lactors in early breast carcinoma. Cancer 74:381-400
37. McGuire WL, Clark GM (1992) Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326:1756-1761
38. Murphy LC (1995) Mechanisms associated with the progression of breast cancer from hormone dependence to independence. Pezoller Foundation J 6-16
39. Early Breast Cancer Trialists' Collobarative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15
40. Fuqua SAW, Chamness GC, McGuire WL (1993) Estrogen receptor mutations in breast cancer. J Cell Biochem 51: 135-139
41. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M (1994) Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264:1455-1458
42. Fujimoto N, Katzenellenbogen BS (1994) Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen-selectivivty mid promotor-dependence. Mol Endocrinol 8:296-304
43. Lahooti H, White R, Danielian PS, Parker MG (1994) Characterization of ligand-dependent phosphorylation of the estrogen receptor. Mol Endocrinol 8:182-188
44. Katzenellenbogen BS, Montano MM, Le Goff P, Schodin DJ, Kraus WL, Bhardwaj B, Fujimoto N (1995) Antiestrogens: mechanisms and actions in target cells. J Steroid Biochem Mol Biol 53:55-64
45. Schuchard M, Landers JP, Sandhu NP, Speisberg TC (1993) Steroid hormone regulation of nuclear proto-oncogenes. Endocrine Rev 14:659-668
46. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494
47. Ferguson AT, Lapidus RG, Baylin SB, Davidson NF (1995) Demethylation of the estrogen receptor gene in estrogen-receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55:2279-2283
48. Iwase H, Greenman JM, Barnes DM, Bobrow L, Hodgson S, Mathew CG (1995) Loss of heterozygosity of the oestrogen receptor gene in breast cancer. Br J Cancer 71:448-450
49. Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M (1990) Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5:1001-1006
50. Taverna D, Antoniotti S, Muggiora P, Dati C, De Bortoli M, Hynes NE (1994) erbB-2 expression in estrogen-receptor-positive breast-tumor cells is regulated by growth-modulatory reagents. Int J Cancer 56:522-528
51. Gudas JM, Nguyen H, Li T, Cowan KH (1995) Hormone-dependent regulation of BRCA1 in human cancer cells. Cancer Res 55:4561-4564
52. Deng G, Chen LC, Schott DR, Thor A, Bhargava V, Ljung BM, Chew K, Smith HS (1994) Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res 54:499-505
53. Wales MM, Biel MA, Deiry WE, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ, Baylin SB (1995) p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Med 1:570-577
54. Devilee P, Cornelisse CJ (1994) Somatic genetic changes in human breast cancer. Biochim Biophys Acta 1198:113-130
55. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821-1828
56. Scherneck S (1995) Contribution of molecular genetic changes for improved management of breast cancer. Onkologie 18:189-201
57. O'Connell P, Pekkel V, Fuqua S, Osborne CK, Allred DC (1994) Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat 32:5-12
58. Ford D, Easton DF (1995) The genetics of breast and ovarian cancer. Br J Cancer 72:805-812
59. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C (1992) The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7:1027-1032
60. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R (1988) Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245
61. Somerville JE, Clarke LA, Biggart JD (1992) c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol 45:16-20
62. Porter PL, Garcia R, Moe R, Corwin DJ, Gown AM (1991) C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer 68:331-334
63. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL (1992) Her-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncology 10: 599-605
64. Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith PJ, Millis RR (1992) Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 28:644-648
65. Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Elliott C, Ashley S, Monaghan P, Harrison S (1988) c-erbB2 expression in benign and malignant breast disease. Br J Cancer 58:453-457
66. Schimmelpennig H, Erikson ET, Falkmer UG, Azavedo E, Svane G, Auer GU (1992) Expression of the c-erbB-2 protooncogene product and nuclear DNA content in benign and malignant human breast parenchyma. Virchows Arch A Pathol Anat 420:433-440
67. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, Terada M, Yamamoto H (1990) Correlation between histologic grade of malignancy and copy number of the c-erbB-2 gene in breast carcinoma. Cancer 65: 1794-1800
68. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA (1990) Immunohostochemical distribution of c-erbB2 in in situ breast carcinoma - a detailed morphological analysis. J Pathology 161:7-14
69. Murphy DS, McHardy P, Coutts J, Mallon EA, George WD, Kaye SB, Brown R, Keith WN (1995) Interphase cytogenetic analysis of erbB2 and topoll alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer 64:18-26
70. An HX, Niederacher D, Beckmann MW, Göhring UJ, Scharl A, Picard F, van Roeyen CRC, Schnürch HG, Bender HG (1995) ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues. Int J Cancer 64:291-297
71. Fantl V, Richards MA, Smith R, Lammie GA, Johnstone G, Allen D, Gregory W, Peters G, Dickson C, Barnes DM (1990) Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Eur J Cancer 26: 423-129
72. Kreipe H, Feist H, Fischer L, Feigner J, Heidorn K, Mettler L, Parwaresch R (1993) Amplification of c-myc, but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res 53:1956-1961
73. Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, Barker EA, Preisler HD (1992) c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res 52:2597-2602
74. Meyers SL, O'Brien MT, Smith T, Dudley JP (1990) Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas. Cancer Res 50:5911-5918
75. Watson PH, Safneck JR, Le K, Dubik D, Shiu RP (1993) Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. J Natl Cancer Inst 85:902-907
76. Berns EMJJ, Foekens JA, van Putten WLJ, van Staveren IL, Portengen H, de Koning WCH, Klijn JGM (1992) Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification. J Steroid Biochem Molec Biol 43:13-19
77. Berns EMJJ, Klijn JGM, van Putten WLJ, van Staveren IL, Portengen H, Foekens JA (1992) c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 52:1107-1113
78. Packham G, Cleveland JL (1995) c-myc and apoptosis. Biochim Biophys Acta 1242:11-28
79. Schuuring E, Verhoeven E, Mooi WJ, Michalides RJAM (1992) Identification and cloning of two overexpressed genes. U21B31/PRad1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 7:355-361
80. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812-1817
81. Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CKW, Musgrove EA, Sutherland RL (1993) Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133
82. Peters G (1994) The D-type cyclins and their role in tumorigenesis. J Cell Science 18:89-96
83. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS (1995) Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Medicine 1:1257-1260
84. Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823
85. Chen LC, Kurisu W, Ljung BM, Goldman ES, Moore II D, Smith HS (1992) Heterogeneity for allelic loss in human breast cancer. J Natl Cancer Inst 84:506-510
86. Chang F, Syrjänen S, Tervahauta A, Syrjänen K (1993) Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer 68:651-661
87. Lynch HT, Lynch J, Conway T, Watson P, Feunteun J, Lenoir G, Narod S, Fitzgibbons R (1994) Hereditary breast cancer and family syndroms. World J Surg 18:21-31
88. Birch JM (1994) Li-Fraumeni. Eur J Cancer 30A: 1935-1941
89. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Patanjale SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NGJ, Taylor AMR, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y (1995) A single ataxia telangiectasia gene with a product similar to PI-2 kinase. Science 286:1749-1753
90. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N (1993) An association between the risk of cancer mutations in the HRAS1 minisatellite locus. N Eng J Med 329: 517-523
91. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigiun S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bodgen C, Dayananth P, Ward J, Tonin P, Narod S, Brislow P, Norris FH, Helvering L, Morrisson P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
92. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Söderquist P, Terry L, Jhanwar S, Berchuck A, Iglehart JD, Marks J, Ballinger DG, Barrett JC, Skolnick MH, Kamb A, Wiseman R (1994) BRCA1 mutations in primary breast cancer and ovarian carcinomas. Science 266:120-122
93. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Pelo J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratum MR (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265:2088-2090
94. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion P, Collins N, Gregory S, Gumhs C, Micklem G, Barfoot R, Hamoudi R, Pantel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop DT, Spurr NK, Ponder BAJ, Eeles R, Pelo J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A Stratton MR (1995) Identification of the breast cancer gene BRCA2. Nature 378:789-792
95. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M, Brody L, Friedman L, Ostermeyer E, Szabo C, King MC, Jhanwar S, Offit K, Norton L, Gilewski T, Lubin M, Osborne M, Black D, Boyd M, Steel M, Ingles S, Haile R, Lindblom A, Olsson H, Borg A, Bishop T, Solomon E, Radice P, Spatti G, Gayther S, Ponder B, Warren W, Stratum M, Liu Q, Fujimura F, Lewis C, Skolnick MH, Goldgar DE (1995) A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. JAMA 273:535-541
96. FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA (1996) Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Eng J Med 334:143-149
97. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Mitchell JT, McArthur-Morrisson J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swensen J, Teng D, Thomas A, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AKC, Shizuya H, Eyfjord JE, Cannon-Albright L, Labrie F, Skolnick MH, Weber B, Kamb A, Goldgar DE (1996) The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12:333-337
98. Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA (1996) BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 334:137-142
99. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL, Chodosh LA (1995) The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 11:17-26
100. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9:444-450
101. Chen Y, Chen CF, Riley DJ, Allred DC, Chen PL, Von Hoff D, Osborne K, Lee WH (1995) Aberrant subcellular localization of BRCA1 in breast cancer. Science 270:789-791
102. Andersen TI, Gaustad A, Ottestad L, Farrants GW, Nesland JM, Tveit KM, Börresen AL (1992) Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas. Genes Chrom Cancer 4: 113-121
103. Cropp CS, Champeme MH, Lidereau R, Callahan R (1993) Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted. Cancer Res 53:5617-5619
104. Futreal PA, Söderquist P, Marks JR, Iglehart JD, Cochran C, Barren JC, Wiseman R (1992) Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphismus. Cancer Res 52:2624-2627
105. Kirchweger R, Zeilinger R, Schneeberger C, Speiser P, Louason G, Theillet G (1994) Patterns of allele losses suggest the existence of five distinct regions of LOH on chromosome 17 in breast cancer. Int J Cancer 56:193-199
106. Knyazev PG, Imyanitov EN, Chernitsa OI, Nikiforova IF (1993) Loss of heterozygosity at 17p is associated with Her-2 amplification and lack of nodal involvement in breast cancer. Int J Cancer 53:11-16
107. Lalle P, De Latour M, Rio P, Bignon YJ (1994) Detection of allelic losses on 17q12-q21 chromosomal region in benign lesions and malignant tumors occurring in a familial context. Oncogene 9:437-442
108. Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G, Nakamura Y (1990) Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res 50:7184-7189
109. Radford DM, Fair KL, Phillips NJ, Ritter JH, Steinbrueck T, Holt HS, Donis-Keller H (1995) Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res 55:3399-3405
110. Lakhani SR, Collins N, Stratton MR, Sloane JP (1995) Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 48:611-615
111. Zhuang Z, Merino MJ, Chuaqui R, Liotta LA, Emmert-Buck MR (1995) Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. Cancer Res 55:467-671
112. Stratton MR, Collins N, Lakhani SR, Sloane JP (1995) Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol 175:195-201.
113. Ito I, Yoshimoto M, Iwase T, Watanabe S, Katagiri T, Harada Y, Kasumi F, Yasuda S, Mitomi T, Emi M, Nakamura Y (1995) Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer. Br J Cancer 71:438-441
114. Hampton GM, Mannermaa A, Winquist R, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee WK, Evans GA (1994) Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res 54:4586-4589
115. Aldaz CM, Chen T, Sahin A, Cunningham J, Bondy M (1995) Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 55:3976-3981
116. Lizard-Nacol S, Lidereau R, Collin F, Arnal M, Hahnel L, Roignot P, Cuisenier J, Guerrin J (1995) Benign breast disease: absence of genetic alterations at several loci implicated in breast cancer malignancy. Cancer Res 55:4416-4419
117. Gudmundsson J, Barkardottir RB, Eiriksdottir G, Baldursson T, Arason A, Egilsson V, Ingvarsson S (1995) Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. Br J Cancer 72:696-701
118. Orphanos V, McGown G, Hey Y, Boyle JM, Santibanez-Koref M (1995) Proximal 6q, a region showing allele loss in primary breast cancer. Br J Cancer 71:290-293
119. Clenton-Jansen AM, Collins N, Lakhani SR, Weissenbach J, Devilee P, Cornelisse CJ, Station MR (1995) Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Br J Cancer 72:1241-1244
120. Beckmann MW, Picard F, An HX, van Roeyen CRC, Dominik SI, Mosny DS, Schnüren HG, Bender HG, Niederacher D (1996) Clinical impact of detection of loss of heterozygosily of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer 73:1220-1226
121. Niederacher D, Picard F, van Roeyen CRC, An HX, Bender HG, Beckmann MW (1997) Patterns of allelic loss on chromosome 17 in sporadic breast cancer detected by fluorescent labelled microsatellite analysis. Genes Chrom Cancer 18:181-192
122. Coles C, Thompson AM, Elder PA, Cohen BB, Mackenzie IM, Cranston G, Chetty U, MacKay J, MacDonald M, Nakamura Y, Hoyheim B, Steel CM (1990) Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis. Lancet 336:761-763
123. MacKay J, Steel CM, Elder PA, Forrest APM, Evans HJ (1988) Allele loss on short arm of chromosome 17 in breast cancers. Lancet 334:1384-1385
124. Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J (1994) p53 mutations in breast cancer. Cancer Res 52: 2095-2097
125. Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, Evans HJ, Steel CM (1992) p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 50:528-532
126. Lindblom A, Skoog L, Andersen TI, Rotstein S, Nordenskjold M, Larsson C (1993) Four separate regions on chromosome 17 show loss of heterozgosity in familial breast carcinomas. Hum Genet 91:6-12
127. Isomura M, Tanigami A, Saito H, Harada Y, Katagiri T, Inanzawa J, Ledbetter DH, Nakamura Y (1994) Detailed analysis of loss of heterozygosity on chromosome band 17p13 in breast carcinoma on the basis of a high resolution physical map with 29 markers. Genes Chrom Cancer 9:173-179
128. Merlo GR, Vanesio T, Bernardi A, Canale L, Gaglia P, Lauro D, Cappa APM, Callaham R. Liscia S (1992) Loss of heterozygosity on chromosome 17p13 in breast carcinomas identifies tumors with high proliferation index. Am J Path 140: 215-223
129. Tsuda H, Callen DF, Fukutomi T, Nakamura Y, Hirohashi S (1994) Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread. Cancer Res 54:513-517
130. Lindblom A, Rotstein S, Skoog L, Nordensjköld M, Larsson C (1993) Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distal metastases. Cancer Res 53:3707-3711
131. Anbazhagan R, Gusterson BA (1994) Prenatal factors may influence predisposition to breast cancer. Eur J Cancer 30A: 1-3
132. Gusterson BA (1995) Prognostic variables and future predictors of behavior and response. In: Senn HJ, Gelber RD, Goldhirsch A, Thurlimann B (eds) Recent results in cancer research. Springer, Berlin Heidelberg New York, pp 89-99
133. Lakhani SR, Slack DN, Hamoudi RA, Colins N, Stratton MR, Sloane JP (1996) Detection of allelic imbalance indicates that the proportion of mammary hyperplasia of usual type is a clonal neoplastic proliferation. Lab Invest 74: 129-135
134. Gusterson BA (1979) Epitheliosis and in situ carcinoma. In: Azzopardi JG (ed) Problems in breast pathology. Saunders, Philadelphia, pp 113-149
135. Berx G, Clenton-Jansen AM, Nollet F, de Leeuw WJF, van de Vijver MJ, Cornelisse C, van Roy F (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 14:6107-6115
136. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, Vincent-Salomon A, Jacquemier J, Birnbaum D, Sobol H (1996) Germ line mutation at BRCA1 affects the histoprognostic grade in heriditary breast cancer. Cancer Res 56:471-474
137. Bos JL (1988) The ras family and human carcinogenesis. Mutation Res 195:255-271
138. Jensen RA, Thompson ME, Jetton TL, Szabo CI, van der Meer R, Helou B, Tronick SR, Page DL, King MC, Holt JT (1996) BRCA1 is secreted and exhibits properties of a granin. Nat Genet 12:303-308
139. Beckmann MW, Niederacher D, Massenkeil G, Tutschek B, Beckmann A, Schenko G, Schnüren HG, Bender HG (1996) Expression analyses of EGF-R and Her-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. Oncology 53:441-447
140. De Bortoli M, Dati C, Antoniotti S, Maggiora P, Sapei ML (1992) Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells. J Steroid Biochem Molec Biol 43:21-25
141. Xiong Y, Zhang H, Beach D (1993) Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 7:1572-1583
142. Detrick DJ, Zhang H, Beach DH (1994) Chromosomal mapping of human CDK2, CDK4, and CDK5 cell cycle kinase genes. Cytogenet Cell Genet 66:72-74
143. Serrano M, Hannon GJ, Beach DA (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D1/CDK4. Nature 366:704-707
144. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL (1993) Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133
145. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812-1817
146. Lee EYHP, To H, Shew JY, Bookstein R, Scully P, Lee WH (1988) Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241:214-221
147. Lungberg C, Skoog L, Cavenee WK, Nordenskjöld M (1987) Loss of heterozygosity in human ductal breast cancer indicates a recessive mutation on chromosome 13. Proc Natl Acad Sci USA 84:2372-2376
148. McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G, Dervan PA (1995) Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. BrJ Cancer 71:981-985
149. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530
150. Xu L, Sgroi D, Sterner CJ, Beauchamp RL, Pinney DM, Keel S, Ueki K, Rutter JL, Buckler AJ, Louis DN, Gusella JF, Ramesh V (1994) Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res 54:5262-5264